Griffin Myers Sells 200,000 Shares of Oak Street Health, Inc. (NYSE:OSH) Stock
Oak Street Health, Inc. (NYSE:OSH – Get Rating) insider Griffin Myers sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $28.63, for a total value of $5,726,000.00. Following the sale, the insider now owns 5,054,159 shares of the company’s stock, valued at approximately $144,700,572.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Oak Street Health Stock Performance
Shares of NYSE OSH traded down $0.05 during mid-day trading on Friday, hitting $28.95. 1,459,671 shares of the company were exchanged, compared to its average volume of 2,574,580. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 16.10. The firm has a market cap of $6.98 billion, a price-to-earnings ratio of -14.62 and a beta of 2.21. The stock has a 50 day simple moving average of $20.37 and a 200-day simple moving average of $20.45. Oak Street Health, Inc. has a 1-year low of $13.29 and a 1-year high of $65.22.
Oak Street Health (NYSE:OSH – Get Rating) last released its earnings results on Tuesday, May 3rd. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). Oak Street Health had a negative return on equity of 413.94% and a negative net margin of 26.82%. The firm had revenue of $513.80 million during the quarter, compared to analyst estimates of $506.82 million. During the same quarter last year, the business posted ($0.29) EPS. The firm’s revenue was up 73.2% on a year-over-year basis. On average, sell-side analysts forecast that Oak Street Health, Inc. will post -2.2 EPS for the current fiscal year.
Institutional Investors Weigh In On Oak Street Health
A number of institutional investors have recently added to or reduced their stakes in OSH. Capital Research Global Investors grew its stake in shares of Oak Street Health by 61.0% during the 1st quarter. Capital Research Global Investors now owns 11,852,080 shares of the company’s stock worth $318,584,000 after purchasing an additional 4,491,941 shares during the period. Maverick Capital Ltd. boosted its holdings in Oak Street Health by 1,464.9% during the fourth quarter. Maverick Capital Ltd. now owns 4,225,127 shares of the company’s stock worth $140,021,000 after buying an additional 3,955,127 shares in the last quarter. Route One Investment Company L.P. grew its position in Oak Street Health by 92.9% during the first quarter. Route One Investment Company L.P. now owns 5,725,037 shares of the company’s stock worth $153,889,000 after buying an additional 2,756,500 shares during the period. Eminence Capital LP purchased a new position in Oak Street Health in the first quarter valued at about $73,233,000. Finally, Capital World Investors increased its holdings in Oak Street Health by 44.5% in the fourth quarter. Capital World Investors now owns 5,966,260 shares of the company’s stock valued at $197,722,000 after buying an additional 1,836,533 shares in the last quarter. Hedge funds and other institutional investors own 91.42% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on OSH. UBS Group assumed coverage on shares of Oak Street Health in a report on Wednesday, April 20th. They set a “neutral” rating and a $26.00 price objective on the stock. Barclays boosted their price target on shares of Oak Street Health from $27.00 to $31.00 and gave the company an “overweight” rating in a research report on Tuesday, April 19th. Bank of America lowered Oak Street Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $26.00 to $18.00 in a report on Wednesday, June 15th. Stifel Nicolaus boosted their target price on Oak Street Health from $25.00 to $35.00 in a report on Wednesday. Finally, Argus began coverage on Oak Street Health in a research report on Tuesday. They issued a “hold” rating for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.81.
About Oak Street Health
Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Oak Street Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Oak Street Health wasn’t on the list.
While Oak Street Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.